Mohammad H Alshaer

Mohammad H Alshaer,

Research Assistant Professor

Department: Pharmacotherapy & Translational Research
Business Email: mshaer@ufl.edu

Teaching Profile

Courses Taught
2020-2023
PHA5782C Patient Care 2: Introduction to Infectious Disease and Oncology
2021-2022
PHA5163L Prac Skills Lab III

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0003-1432-5175

Publications

2024
A Randomized Clinical Trial of Bayesian-Guided Beta-Lactam Infusion Strategy and Associated Bacterial Resistance and Clinical Outcomes in Patients With Severe Pneumonia.
Therapeutic drug monitoring. 46(1):95-101 [DOI] 10.1097/FTD.0000000000001144. [PMID] 38018847.
2024
Association of piperacillin and vancomycin exposure on acute kidney injury during combination therapy.
JAC-antimicrobial resistance. 6(1) [DOI] 10.1093/jacamr/dlad157. [PMID] 38259903.
2024
Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients.
Pulmonary pharmacology & therapeutics. 84 [DOI] 10.1016/j.pupt.2023.102271. [PMID] 38008397.
2024
Response to comment on “International consensus recommendations for the use of prolonged-infusion β-lactams endorsed by the American College of Clinical Pharmacy (ACCP), the British Society for Antimicrobial Chemotherapy (BSAC), the Cystic Fibrosis Foundation (CFF), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), the Infectious Diseases Society of American (IDSA), the Society of Critical Care Medicine (SCCM), and the Society of Infectious Diseases Pharmacists”.
Pharmacotherapy. 44(2):208-209 [DOI] 10.1002/phar.2907. [PMID] 38362632.
2023
Adequacy of WHO weight-band dosing and fixed-dose combinations for the treatment of TB in children.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 27(5):401-407 [DOI] 10.5588/ijtld.22.0591. [PMID] 37143230.
2023
Beta-lactam target attainment and associated outcomes in patients with bloodstream infections.
International journal of antimicrobial agents. 61(3) [DOI] 10.1016/j.ijantimicag.2023.106727. [PMID] 36646230.
2023
Cefepime Daily Exposure and the Associated Impact on the Change in Sequential Organ Failure Assessment Scores and Vasopressors Requirement in Critically Ill Patients Using Repeated-Measures Mixed-Effect Modeling.
Critical care explorations. 5(11) [DOI] 10.1097/CCE.0000000000000993. [PMID] 38304706.
2023
Effect of HIV infection on plasma exposure to first-line TB drugs and target attainment in children.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 27(12):931-937 [DOI] 10.5588/ijtld.23.0184. [PMID] 38042977.
2023
Experience with Implementing a Beta-lactam Therapeutic Drug Monitoring Service in a Burn Intensive Care Unit: A Retrospective Chart Review.
Journal of burn care & research : official publication of the American Burn Association. 44(1):121-128 [DOI] 10.1093/jbcr/irac099. [PMID] 35896122.
2023
Impact of Beta-Lactam Target Attainment on Resistance Development in Patients with Gram-Negative Infections.
Antibiotics (Basel, Switzerland). 12(12) [DOI] 10.3390/antibiotics12121696. [PMID] 38136730.
2023
International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists.
Pharmacotherapy. 43(8):740-777 [DOI] 10.1002/phar.2842. [PMID] 37615245.
2023
International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists: An executive summary.
Pharmacotherapy. 43(8):736-739 [DOI] 10.1002/phar.2844. [PMID] 37615244.
2023
Making the case for precision dosing: visualizing the variability of cefepime exposures in critically ill adults.
The Journal of antimicrobial chemotherapy. 78(9):2170-2174 [DOI] 10.1093/jac/dkad211. [PMID] 37449472.
2023
Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 76(3):497-505 [DOI] 10.1093/cid/ciac511. [PMID] 35731948.
2023
The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation.
International journal of antimicrobial agents. 62(4) [DOI] 10.1016/j.ijantimicag.2023.106939. [PMID] 37517627.
2023
Therapeutic drug monitoring in cystic fibrosis and associations with pulmonary exacerbations and lung function.
Respiratory medicine. 212 [DOI] 10.1016/j.rmed.2023.107237. [PMID] 37030586.
2023
Use of therapeutic drug monitoring to characterize cefepime-related neurotoxicity.
Pharmacotherapy. 43(1):6-14 [DOI] 10.1002/phar.2744. [PMID] 36401796.
2023
Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. [DOI] 10.1177/10781552231213883. [PMID] 37981806.
2023
Why is the Implementation of Beta-Lactam Therapeutic Drug Monitoring for the Critically Ill Falling Short? A Multicenter Mixed-Methods Study.
Therapeutic drug monitoring. 45(4):508-518 [DOI] 10.1097/FTD.0000000000001059. [PMID] 37076424.
2022
Another trial for the TARGET trial.
Intensive care medicine. 48(6):774-775 [DOI] 10.1007/s00134-022-06654-9. [PMID] 35230463.
2022
Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics.
Antimicrobial agents and chemotherapy. 66(2) [DOI] 10.1128/AAC.02046-21. [PMID] 34902271.
2022
Cerebrospinal fluid concentrations of fluoroquinolones and carbapenems in tuberculosis meningitis.
Frontiers in pharmacology. 13 [DOI] 10.3389/fphar.2022.1048653. [PMID] 36578553.
2022
Clinical Pharmacokinetics and Pharmacodynamics of Cefepime.
Clinical pharmacokinetics. 61(7):929-953 [DOI] 10.1007/s40262-022-01137-y. [PMID] 35764774.
2022
Cycloserine and Linezolid for Tuberculosis Meningitis: Pharmacokinetic Evidence of Potential Usefulness.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 75(4):682-689 [DOI] 10.1093/cid/ciab992. [PMID] 34849645.
2022
Effect of Rifabutin in Dolutegravir Dosing: A Case Series.
Journal of the International Association of Providers of AIDS Care. 21 [DOI] 10.1177/23259582221111077. [PMID] 36026587.
2022
Effectiveness and Safety of Beta-Lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with Pseudomonas aeruginosa Pneumonia or Bloodstream Infection.
Antimicrobial agents and chemotherapy. 66(10) [DOI] 10.1128/aac.00646-22. [PMID] 36073943.
2022
Enteropathogen spectrum and effect on antimycobacterial pharmacokinetics among children with tuberculosis in rural Tanzania: a prospective cohort study.
The Lancet. Microbe. 3(6):e408-e416 [DOI] 10.1016/S2666-5247(21)00308-6. [PMID] 35659902.
2022
Implementation of a β-lactam therapeutic drug monitoring program: Experience from a large academic medical center.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 79(18):1586-1591 [DOI] 10.1093/ajhp/zxac171. [PMID] 35704702.
2022
Linezolid Exposure Is Associated with Cytopenias in Patients Treated for Multidrug-Resistant Tuberculosis.
Antimicrobial agents and chemotherapy. 66(9) [DOI] 10.1128/aac.00408-22. [PMID] 35916515.
2022
Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue.
Antimicrobial agents and chemotherapy. 66(8) [DOI] 10.1128/aac.00438-22. [PMID] 35862739.
2022
Pharmacogenetic testing for NAT2 genotypes in a Tanzanian population across the lifespan to guide future personalized isoniazid dosing.
Tuberculosis (Edinburgh, Scotland). 136 [DOI] 10.1016/j.tube.2022.102246. [PMID] 35961094.
2022
Using Machine Learning To Define the Impact of Beta-Lactam Early and Cumulative Target Attainment on Outcomes in Intensive Care Unit Patients with Hospital-Acquired and Ventilator-Associated Pneumonia.
Antimicrobial agents and chemotherapy. 66(7) [DOI] 10.1128/aac.00563-22. [PMID] 35699444.
2021
Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study.
Implementation science communications. 2(1) [DOI] 10.1186/s43058-021-00134-9. [PMID] 33762025.

Contact Details

Emails:
Business:
mshaer@ufl.edu
Addresses:
Business Mailing:
RM P4 05 PO Box 100486
1600 SW ARCHER RD
GAINESVILLE FL 32610